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PHP12
Review Of RefeRence PRicing effects On PHaRmaceuticals
Zhou W., Cui X., Qian Y.
Sanofi China, Beijing, China
Objectives: Reference pricing has been popular used in many countries as a reim-
bursement policy to contain raising pharmaceutical expenditures since Germany 
first introduced in1989. China is under discussion concerning implementation of 
reference pricing for innovative drug pricing. This study is designed to overview 
the effects of reference pricing on health care helps to provide reference evidence 
to estimate the potential role of reference pricing for policy strategy making, and 
deliver the suggestion on benefit/risk analysis when adopting reference pricing in 
China. MethOds: We systematic reviewed published review studies or literatures 
based on empirical outcome effects analysis of reference pricing and present the 
common assess conclusion or views on the effect of reference pricing across all 
experiences, selected research covered different countries and backgrounds have lit-
tle coverage to keep the references outcomes diversity and little overlap. Results: 
Results shows that reference pricing could decreases drug prices include in system 
and original and generic drug price reductions are different according to pharma-
ceutical markets power. Reference pricing increases drug use of priced below or at 
the reference price. Reference pricing could save drug expenditures limited in the 
short-run but no sufficient evidence showed on the long-term expenditures reduc-
tion. Besides, no adverse effect was clearly found on patient access pharmaceutical 
services by reference pricing. cOnclusiOns: Evidences indicates that reference 
pricing seems to be effective for governments to contain pharmaceutical expendi-
tures and more research is need on the long-term effects and impact on different 
health care systems of reference pricing.
PHP14
QuestiOnnaiRe analysis On PHaRmacists ROle and dRug 
ReimbuRsement list adjustment mecHanism undeR tHe cuRRent 
cHina HealtH insuRance system
Song R.1, Xuan J.2, Chen C.1, Wang M.1, Xie X.3
1China Pharmaceutical Research and Development Association, Beijing, China, 2Fudan University, 
School of Public Health, Warren, NJ, USA, 3Pfizer China, Beijing, China
Objectives: To study how to adjust the roles of pharmacists under the currently 
health insurance system; and how to perfect the mechanism for drug reimbursement 
list adjustment under China. current social health insurance system MethOds: 
China Pharmaceutical Industry Research and Development Association formulated 
the Questionnaire on the Roles of Pharmacists and the Health Insurance System. Survey 
was conducted to pharmacists and experts in relevant fields from early April 2013. 
By the middle of May, 152 questionnaires were returned, in which 141 ones were 
considered effective for the statistics. Results: As to the pharmacist system, 95% 
respondents agree to popularize the pharmacist system comprehensively in the 
hospitals. Respondents believe that pharmacists shall be entitled to the rights of 
verifying prescriptions, examining medication cost information, dispensing high 
quality drugs with preference, and participating in RDL adjustment. The majority 
of respondents (81.6%) agree to link the medical institutions and medical insurance 
agencies on line, which can better take advantage of pharmacistsrole. As to the RDL 
adjustment cycle, most respondents (78.7%) believe that current 4-year cycle is not 
reasonable, and more people (46.8%) think 2 years may be better. The respondents 
think that major problems in current RDL adjustment mechanism lie in the lack of 
evaluationstandards and procedures transparency. More people (61.0%) agree that 
the pharmacoeconomics evaluation shall be an essential basis for RDL adjustment 
decisions process. The survey results also show that at present, the system design 
for pharmacoeconomics application is not mature, and relevant capacity building 
and legislative guarantee are urgently required. cOnclusiOns: It has been a com-
monly recognization to improve the pharmacist system and strengthen the rights 
of pharmacist in prescription examination and drug dispensing. Evidence-based 
researches on how to shorten adjustment cycle, establish a transparent and open 
decision-making process, and attach importance to the pharmacoeconomics are 
major issues needing improvements in the present RDL adjustment mechanism.
PHP15
HOw dO ORganizatiOnal aRRangements Of tHe PHaRmaceutical 
suPPly system affect availability tO essential medicines  
in RuRal cHina?
Zuo G.
Shandong University, Jinan, China
Objectives: The manifold reasons lead to lack of availability to essential medicines, 
but higher price induced by pharmaceutical patent and organizational arrange-
ments of pharmaceutical supply system is main barrier. Since 2009, Chinese govern-
ment has constructed essential medicines policy of centralized purchasing, uniform 
distribution and “zero-mark-up” (i. e. no-profit) sale to supply essential medicines, 
all but generic drugs. This study aims to develop a theoretical methodology to 
examine the impact of organizational arrangements on availability to essential 
medicines. MethOds: We present a theoretical framework based on organizational 
economics to identify organizational boundary and inter-organization relationship 
of pharmaceutical supply system in order to define the stakeholders’ function and 
to find competition and cooperation relationship between them. We collect evidence 
from nine township hospitals at three counties of Shandong Province with different 
economic and geographical environment from July to August 2011. Organizational 
arrangements are identified by document review, interviews and focus group discus-
sions with stakeholders. Availability to essential medicines is measured as allocated 
rate and timeliness arrival rate of national essential medicines by questionnaire and 
online transaction records. Results: The mean allocated rate of national essential 
medicines was 51.47% because organizational boundary between stakeholders was 
so vague that the stakeholders’ function was not clear and pharmaceutical manu-
facturers didn’t receive the demand information of township hospitals. Timeliness 
arrival rate of national essential medicines within three days was from 33.77% 
Objectives: This study estimates the effect of national essential drug system on 
drug price and patient selection of pilot grass-root medical institution. MethOds: 
This study employs DID (difference-in-difference) method to investigate the effect 
of Essential Drug Regime Reform (EDRR) on drug price and patient selection of 
public grass-root medical institutions. Our sample comes from a Chinese city’s 
Urban Employee Basic Medical Insurance Reimbursement Dataset for inpatient 
care from 2009-2010. The full sample has 53416 observations including 2896 unique 
pharmaceutical firm-level products from 210 grass-root medical institutions. The 
dependent variable is the average price of each product in each month from each 
medical institution. The key independent variables are dummy variables indicating 
the pilot institutions (TREAT), the releasing time of Essential Drug Regime (EDR) 
and interaction of them (TREAT*EDR). Results: The results show that after the 
implementation of EDR, drug price on the pilot institutions decreased significantly 
by 37 percent (relative to control institution). Especially, essential drugs fell by 
43.3 percent relative to control institution. This policy has no significant effect on 
non-essential drugs. After the implementation of the national essential drug sys-
tem inpatient expenditures of the pilot medical institutions increased by 20.67%, 
length of stays increased by about three days, relative to the non-pilot medical 
institutions. After all, there is no change in patient co-payment rate. We found that 
patients more severe (diagnosed with more than one diseases) chose to go to the 
pilot medical institution increased by 7%. cOnclusiOns: The national essential 
drug systerm has signifcant effect on durg price, especially the essential drug, 
and the patients more severe prefered to go to the grass-root medical institution 
rather than levle-2 and level-3 hospitals.
PHP10
an analysis Of deteRminants Of new and bland-name dRugs 
PRescRiPtiOn beHaviOR amOng jaPanese PHysicians
Ma X., Kakihara H.
Kyoto University, Kyoto, Japan
Objectives: Japanese government has promoted the use of generic drugs as 
means to decrease the burden to patients as well as to improve the situation of 
public finance sustainability. However, the proportion of generic prescriptions out 
of the total prescriptions written is lower compared to other developed countries. 
We thus examine the determinants of prescription of new and brand name drugs 
to understand what discourages Japanese physicians from prescribing generic 
drugs. MethOds: Using data from an original survey of 300 physicians conducted 
in September 2012. These surveys are analyzed with regard to the potential influ-
ence of the following factors: physicians’ information seeking behavior regard-
ing drugs, principal-agent relationship, risk and time preferences and physician 
characteristics. The analysis uses an ordered logistic regression model. Results: 
Our major findings are summarized as follows. First, it can be said that the propor-
tion of new drug prescriptions to all prescriptions rises as physicians’ intensity 
in information seeking behavior increases, but it is not significantly affected by 
principle-agent relationship or risk or time preferences. Second, the proportion of 
brand name drug prescriptions is positively associated with increased consideration 
of drug safety but negatively associated with that of drugs costs, pointing toward 
the hypothesis that the principal-agent relationship is an important factor. Third, 
time preference significantly determines the prescription of brand name drugs 
whereas risk preference does not. In particular, the more preferred is current con-
sumption over future consumption, the greater proportion of brand name drugs is 
prescribed. Neither risk nor time preferences significantly affects the proportion 
of prescription of new drugs. Finally, the impact of each determinant on prescrip-
tion behavior differs between internal medicine physicians and physicians in other 
areas of specialization. cOnclusiOns: Our empirical results suggest a limitation 
of uniform policies across physicians such as provision of financial incentives as 
means to the promotion of generic drug use.
PHP11
Review On medicines PRices and availability in indOnesia: 2004  
tO 2012
Siahaan S., Handayani R.S.
National Institute of Health Research and Development (NIHRD), Jakarta Pusat, Indonesia
Objectives: In 2014 Indonesia started National Health Insurance (NHI). This 
study aimed to search the existing evidence base on access to medicine issues to 
recommend policy options and model of medicines prices to be used in the era 
of NHI. MethOds: NIHRD conducted study at 2012 by reviewing several surveys 
results of access to medicines from 2004-2012 and organising several discussion 
forums about access to medicines. The participants were key persons from govern-
ment, private sectors, NGOs and other related stakeholders. Results: Indonesia 
medicines prices surveys using WHO-HAI method in 2004, 2010 and 2012 showed 
access to medicines problems still had similar patterns i. e. several district health 
offices bought medicines with higher prices than national standard prices and sev-
eral public hospitals sold several medicines with higher prices than private sectors. 
Most medicines prices (> 90%) were still higher than international reference price. 
The Median Price Ratios (MPRs) of medicines for public sector in Indonesia were 
1.74 (2004) and 1.52 (2012), while in Malaysia was 1.09 (2004) and in Thailand was 
1.46 (2006), but in Philippine was 2.06 (2009). The availability of medicines in public 
sectors was consistent lower than in private sectors. Study (2007) showed the avail-
ability of several essential and generic medicines in several public health facilities 
were enough for < 3 months. Study (2011) showed availability of FDC medicines for 
tuberculosis and ACT for malaria in endemic areas were inadequate (50%&70%). 
Discussion forums summarized main points: Medicines prices can be controlled 
by full time pharmacist if they serve rational drug use to patients. NHI has ability 
to control medicines prices, etc. cOnclusiOns: Pharmacy should not “mark-up” 
medicines prices, but charge pharmacist services fee to patients. The government 
should set up MPRs of medicines in the list of NHI formulary no more than 1.50 
and assure its availability, and NHI should implement pharmacoeconomics for new 
medicines.
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models, and represents those where cost is the main determinant of outcomes. The 
latter includes the more developed Shanghai model which encompasses a more 
holistic approach with consideration for the quality, patent status and degree of 
innovation of a medicine. Analysis of published tender results shows a significant 
variation between the resultant prices in different provinces, with as much as 50% 
difference between the tender price and MRP set by the NDRC. Price erosion is 
greatest for generic medicines and those where a larger degree of competition 
exists, indicating that market forces ultimately have the greatest effect on tendering 
outcomes. cOnclusiOns: Our results demonstrate the large degree of variation 
between tendering processes in China. Although “price focused” models typically 
result in high downwards pricing pressure, “quality focused” models are more recep-
tive of innovative medicines, thus, achieving price premiums is possible.
PHP19
Recent RegulatORy RefORms tO ensuRe Patient safety in clinical 
ReseaRcH in india
Gupta S.K.
DIPSAR, University of Delhi, NEW DELHI, India
Objectives: To study the Regulatory reforms and its impact on Clinical Trials in 
India. The present study involves the lacune in conducting Clinical Trials and pre-
sents the Regulatory reforms in India. MethOds: India is an emerging destination 
for Clinical Research because of its genetic pool, availability of patients for enrol-
ment, infrastructure and talented pool of physicians. In order to ensure patient 
safety in Clinical Trials several regulatory reforms have been implemented by the 
ministry of health and family welfare, Govt. of India. These include constitution of 
ethics committee’s, audio video recording of the consent, audit and inspections of 
the sites, registration of ethics committee’s etc. Compensation policy for deaths dur-
ing the clinical trials have been framed. In order to ensure patient safety, National 
Pharmacovigilance Programme of India (PvPI) have been launched in the country 
for the safety monitoring of drugs as a post marketing surveillance. PvPI is work-
ing in coordination with the WHO Uppsala Monitoring Centre. The presentation 
will discuss the salient regulatory reforms for patient’s safety in clinical research 
in India. Results: In order to ensure the safety of patients, the reporting culture 
of the Adverse Drug Reactions have been improved. There is a pool of 70000 ADR’S 
in the PvPI database and number of ADR Centres have been increased to 150 in 
various parts of the country. With the implementation of new Regulatory reforms, 
there is tranparency in the system. Culture of Reporting ADR’S by the physicians 
have also increased. The Ethical Review Boards have been prooperly strengthened, 
Serious Adverse Drug Reactions are being reported to the regulatory agency and 
compensations are being paid in the Clinical Trials. cOnclusiOns: It is concluded 
that the new Regulatory Reforms will ensure the safety of the patients during the 
Clinical Trials.
PHP20
dRug utilizatiOn PatteRn fOR tHe tReatment Of sePtic sHOck in 
tHe icu: a cOmPaRisOn between suRvivORs and nOn-suRvivORs in a 
teRtiaRy caRe teacHing institute
Hom Choudhuri A., Uppal R.
GB Pant Hospital & Maulana Azad Medical College, New Delhi, India, Delhi, India
Objectives: To describe the drug utilization pattern in the treatment of patients 
with septic shock in the ICU. MethOds: Setting: 7-bed mixed medical/surgical 
intensive care unit (ICU) of a tertiary care teaching hospital. A retrospective cohort 
study of patients with septic shock, who were treated in the ICU between January 
2012 and December, 2013. The ICU database was used to identify the patients. The 
patient demographics and characteristics were recorded. In addition, the number 
and type of prescribed medications, type of infection, and culture results were deter-
mined. The main outcomes were the type of medication classes utilized and their 
comparison between the survivors & non-survivors. Results: During the study 
period, 109 cases were identified. Upon presentation, the mean Acute Physiology 
and Chronic Health Evaluation II (APACHE II) score was 22.5 (SD ±7.8), 93 (85.3 %) 
patients had leucocytosis, and 84 (77.0 %) had positive cultures. The mean num-
ber of medications prescribed per patient was 11.7 (SD ±4.7). The most commonly 
prescribed medication classes were proton pump inhibitors, carbapenems, BL/BLI 
combinations and vasopressors prescribed in 101 (92.6 %), 75 (68.8 %), 64 (58.7 %), and 
91 (83.4 %) patients, respectively. Antifungals and blood products were prescribed 
in 45 (41.2 %) and 77 (70.6 %) patients, respectively. Medication usage were higher 
in non-survivors, compared to survivors (12.6 ± 2.4 versus 9.7±4.1), and in patients 
with positive cultures (13.5±1.9 versus 9.3± 3.6) compared to patients with negative 
cultures. cOnclusiOns: In patients with severe sepsis and septic shock, multiple 
medications were prescribed, and the use of medications was higher in the non-
survivors in comparison to the survivors.
PHP22
use Of medicatiOns in tHe event Of jOb lOss
Liu X.
University of Central Florida, Oviedo, FL, USA
Objectives: Jos loss has been shown to negatively affect displaced workers’ 
health. But it remains unclear how job loss affects medication use and spending 
on prescription drugs. The purpose of this study was to examine the impact of job 
loss on the use of medications as measured by out-of-pocket payment for the last 
prescription. MethOds: A quasi-experimental design was used to study workers 
who did and did not experience involuntary job displacement. The data was drawn 
from four waves of the Medical Expenditure Panel Survey (MEPS), taken in 2008, 
2009, 2010, and 2011. Involuntary job loss was defined as job separation due to 
“job ended” or “business dissolved or sold”. Our analysis was limited to adults who 
participated in all five rounds of interviews. Results: While the average out-of-
pocket payment for the last prescription remained unchanged for those remained 
employed (around $23.10), the spending for those lost job increased by $2.82 ($19.41 
vs. $22.23). Compared with those who remained employed, those who experienced 
to 71.45% because of unfair competition between pharmaceutical distribution 
companies and cooperation failure between pharmaceutical manufacturers and 
pharmaceutical suppliers. cOnclusiOns: Successful pharmaceutical supply sys-
tem of essential medicines needs to clearly define the function and to coordinate 
competition and cooperation relationship between pharmaceutical manufacturers, 
distribution companies and township hospitals. KeywORds: essential medicine; 
availability; organizational arrangement.
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classificatiOn Of dRugs bRinging fROm abROad in tuRkey accORding 
tO tHeiR atc cOdes
Tuna E., Atikeler K., Calýskan Z.
Hacettepe University, Ankara, Turkey
Objectives: There have been several strict cost containment measures, as refer-
ence pricing system and global budget, being aplied in Turkish health care system 
especially for drugs. As a result of these measures; most of the drugs being marketed 
in Turkey have the lowest price in Europe. In this regard, several drugs including 
the drugs being used in critical diseases such as cancer, orphan diseases etc, have 
been withdrawn from the market or even they wouldn’t be able to enter the market. 
Therefore, Turkish government brings these drugs from abroad by paying much 
more money compared to the current or the future prices (the price if the drug 
would have licenced or being reimbursed) of those drugs in Turkey. The aim of this 
study is to analyze the list of these drugs according to their ATC groups. MethOds: 
The list of Social Security Institution (SSI) on drugs bringing from abroad (Annex 4 
C) have been analyzed in assistance with RxMediaPharma® Program. Results: In 
total, there are 662 drugs being listed in the latest Annex 4-C list. Among this list; 
the most frequently listed ATC group is L (antineoplastic and immunomodulating 
agents) by 22%, second is A (alimentary tract and metabolism) by 13.3%, third is C 
(cardiovascular system) by 12.5%, fourth and fifth are; N (nervous system) by 12% 
and J (antiinfectives for systemic use) by 6,35% relatively. cOnclusiOns: Strict 
cost containment measures being applied in Turkey causes shortages of several 
drugs especially the ones being used in diseases with high mortality rates like 
cancer. In this situation, despite government has brought these medicines from 
abroad, as this procedure takes some time, patients may have trouble in reaching 
these drugs on time and SSI pays much more for these drugs compared to their 
probable prices in Turkey.
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PRicing and ReimbuRsement POlicy uPdates in asia
Paranjoy S., Kaushik P., Kaur S., Sharma S., Sehgal M.
HERON™ Commercialization, PAREXEL® International, Chandigarh, India
Objectives: Pharmacoeconomics and outcomes research (PEOR) has emerged as 
a key decision-making tool to optimize patient care and add value to health care 
services. Considering the strategic importance of Asian markets and economic con-
straints in the pharmaceutical sector, an understanding of current pricing strategies 
become vital for market authorization holders as well as payers. MethOds: An 
assessment of health care policies, pricing systems, and reforms impacting reim-
bursement and market access environment was undertaken across major Asian 
markets (Japan, China, South Korea, and India). Information sources included online 
portals of regulatory agencies and relevant keyword searches. Results: Health 
policy decisions over recent years have indicated varying levels of priorities and 
interests within Asia. Japan continues to increase health care investments and 
attempts are being made to expedite drug approval process. Despite a robust pricing 
mechanism, Japanese pharmacoeconomic guidelines are yet to be implemented. 
Public health expenditure in China has witnessed almost 50% growth since 2004. 
Chinese pharmacoeconomic guidelines are now in practice and pricing norms 
have gained more structure with the introduction of external referencing and price 
negotiations with drug companies. In South Korea, pharmacoeconomic guidelines 
are well-established and the current focus is on cost-containment measures like 
profit controls and price cuts. Pharmacoeconomics in India is still in its nascent 
stage but the 2013 Drugs (Prices Control) Order (DPCO) included radical changes 
focussing on market-based pricing. Furthermore, the introduction of price negotia-
tion mechanisms is also being considered by the Department of Pharmaceuticals 
(DoP) in India. cOnclusiOns: The focus on PEOR by reimbursement agencies in the 
West has compelled their Asian counterparts to revisit pricing policies. Japan has 
started drafting pharmacoeconomic guidelines, while Chinese and South Korean 
governments have implemented new mechanisms to manage drug prices. In India, 
the DoP has encouraged revisions in the DPCO and further reforms in pricing mecha-
nisms are expected in the near future.
PHP18
PROvincial HOsPital tendeRing in cHina: evaluating tHe imPact  
On PRice
Sherwin G.1, Saraf S.1, Li X.2, Akpinar P.1
1ICON Pricing and Market Access, London, UK, 2ICON Commercialisation & Outcomes, London, UK
Objectives: In China, maximum retail prices of reimbursed medicines are con-
trolled at the national level by the National Development and Reform Commission 
(NDRC). At the provincial level, different tendering processes are used to procure 
medicines, often resulting in disparity between provinces and a significantly lower 
final price than the MRP. The objective of this research is to understand the dif-
ferent provincial tendering models and evaluate the resultant effect on medi-
cine prices. MethOds: We conducted secondary research of both national and 
provincial government websites to identify the different tendering models used 
across China. Provincial tender results were analyzed to understand the final 
price variation between provinces, relative to the MRP. Finally, primary research 
was conducted with payers in provinces with well-established tendering models - 
including Anhui, Beijing, Fujian, Hebei and Shanghai - to understand the individual 
nuances. Results: Tendering models exist on a continuum between “price focused” 
and “quality focused” processes. The former includes both the Anhui and Fujian 
